Procaps Group, S.A. PROCW
Set alert
At close · Mar 12
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0194
- Prev close
- 0.0194
- Mkt cap
- 1.96M
- Vol
- 282.52K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0194
- High
- 0.0194
- Forward P/E
- 0.00
- Beta
- 0.17
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.10
- EPS (TTM)
- 0.00
- Beta
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.61%
- Revenue (TTM)
- 414.10M
- Revenue growth
- 7.30%
- Free cash flow
- -12.18M
- Total cash
- 17.56M
- Total debt
- 289.92M
- Return on equity
- 373.70%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Procaps Group, S.A.
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Luxembourg
- Website
- procapsgroup.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PROCW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Highbridge Capital Management, LLC. | 6.64% | 1,552,619 | 62.10K | Sep 29, 2024 |
| Walleye Capital LLC | 5.52% | 1,289,742 | 51.59K | Sep 29, 2024 |
| Walleye Trading LLC | 3.11% | 726,315 | 29.05K | Sep 29, 2024 |
| Davidson Kempner Capital Management LP | 2.34% | 547,600 | 21.90K | Sep 29, 2024 |
| Cowen and Company, LLC | 2.17% | 507,251 | 20.29K | Sep 29, 2024 |
| Tenor Capital Management Co., L.p. | 1.71% | 400,000 | 16.00K | Sep 29, 2024 |